Gene therapy for neurological disorders: progress and prospects.

Area of Science:

• Neurology
• Gene Therapy
• Viral Vector Technology

Background:

• Adeno-associated viral (AAV) vectors are a rapidly advancing gene therapy platform.
• AAV vectors are being explored for treating various neurological diseases.
• Successful delivery of therapeutic payloads to the central nervous system has been demonstrated in preclinical models.

Purpose of the Study:

• To discuss key considerations and challenges in designing and developing therapeutic AAV vectors.
• To highlight promising therapeutic targets for AAV-based gene therapy.
• To review recent clinical advances in AAV vector applications for neurological disorders.

Main Methods:

• Review of preclinical studies involving AAV vector delivery of transgenes (proteins, microRNAs, antibodies, gene-editing tools).
• Analysis of various administration routes and capsid engineering for CNS targeting.
• Evaluation of initial clinical trial data for safety, efficacy, and durability of transgene expression.

Main Results:

• Preclinical success in delivering diverse genetic materials to the central nervous system using AAV vectors.
• Initial clinical studies show encouraging safety and efficacy profiles for AAV therapies in Parkinson disease and spinal muscular atrophy.
• Demonstrated durability of transgene expression in clinical settings.

Conclusions:

• AAV vectors represent a significant gene therapy platform for neurological conditions.
• Future development requires addressing design considerations and challenges for optimal therapeutic outcomes.
• Ongoing research and clinical trials are crucial for advancing AAV-based treatments for neurological diseases.